PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy

About this update from Pharmacorp Rx Inc.

Saskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the "Corporation"), a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, today announced that it entered into a definitive share purchase agreement dated June 26, 2026 (the "Agreement") to acquire 100% of the issued and outstanding shares of a PharmaChoice bannered pharmacy located in Western Canada (the "Acquisition"). "This transaction reflects the continued execution of our acquisition strategy and demonstrates our ability to convert previously announced LOIs into definitive agreements," said Alan Simpson, Executive Chair of PharmaCorp. "The pharmacy we are acquiring has a strong operating foundation, an established patient base, and a transition plan that aligns well with our pharmacist-led operating model." Further to PharmaCorp's acquisition pipeline update announced on April 30, 2026, in which the Corporation disclosed four non-binding LOIs in additional pharmacy acquisitions (the "Previously Announced LOIs"), this Acquisition represents the second of those four Previously Announced LOIs to be converted into a definitive share purchase agreement. Upon completion of the Acquisition, and assuming completion of the previously announced eight-store acquisition in Eastern Canada and the previously announced Ontario acquisition, PharmaCorp is expected to operate 16 community pharmacies in Canada. The eight-store acquisition in Eastern Canada remains on track to close in early July 2026 and the Ontario acquisition remains on track to close in late July 2026. Further Details Of The Acquisition The aggregate purchase price for the Acquisition announced today is approximately $2,470,000, subject to customary adjustments (the "Purchase Price"), and is expected to be funded using the Corporation's existing cash resources. The Acquisition is expected to close in late July, subject to customary closing conditions, including receipt of all required regulatory approvals. No finder's fees are payable in connection with the Acquisition. The Acquisition is consistent with PharmaCorp's acquisition framework and broader capital allocation strategy, including its disciplined approach to valuation, integration and long-term growth.

View stock analysis, news, and events for Pharmacorp Rx Inc.